Nxera Pharma Co., Ltd. · TSE:4565
Nxera Pharma — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
25 slides from Nxera Pharma's conference presentation, Jan 13, 2026
Slide 1: Leading the next era of medicine. From Japan, for Japan, and the world.
NON-CONFIDENTIAL Leading the next era of medicine. From Japan, for Japan, and the world. 44th Annual J.P. Morgan Healthcare Conference 13 January 2026
Slide 2: Disclaimer
The material that follows is a presentation of general background information about Nxera Pharma Co., Ltd and its subsidiaries (collectively, the “Company”) as of the date of this Disclaimer presentation. This material has been prepared solely for informational purposes and is not to be construed as
Slide 3: Chris Cargill, President & CEO
Chris Cargill President & CEO Nxera Pharma (TSE:4565) 3
Slide 4: Not a traditional Japanese pharma
Not a traditional Japanese pharma. We think and innovate globally, and specialize locally Drug Discovery Platform Commercial CEO Research Finance Chief of Staff Legal Finance Operation Compliance Research & Early Clinical • Cryo-EM Nobel Prize winning founder • Proprietary StaR and NxWaveTM structur
Slide 5: Both sides of the business continue to advance rapidly
Both sides of the business continue to advance rapidly Drug Discovery Platform Commercial Clinical Asset Products Active Programs Changes in 2025 2025 Sales Changes in 2025 (Median target: JPY) (Median target) Phase 3 2 +2 PIVLAZ® 13.5Bn +7% Phase 2 5 +2 QUVIVIQ® 4.5 Bn +220% Phase 1 8 -2 (moved to
Slide 6: Commercial business in Japan and APAC
Commercial business in Japan and APAC
Slide 7: Our late-stage and commercialized assets in Japan and APAC
Our late-stage and commercialized assets in Japan and APAC Commercial Discovery – Preclinical Phase 1 Phase 2 Phase 3 Filed Commercial Vamorolone A PIVLAZ® A IN-HOUSE CNS IMM Duchenne Muscular Dystrophy Cerebral vasospasm EP4 ag. NXE’744 Lucerastat A QUVIVIQTM A Best-in-class SMEs for IBD Fabry dise
Slide 8: Our two commercial products in Japan are showing significant sales growth yoy
Our two commercial products in Japan are showing significant sales growth yoy Commercial Target 13.0 - 14.0 Bn JPY (PIVLAZ®) from net sales, and 4.0 - 5.0 Bn JPY (QUVIVIQ®) from royalties and supply Target sales in FY2025 13.0 – 14.0 Bn JPY +7% 4.0 – 5.0 Bn JPY +220% (NHI Sales:15.7 – 16.9Bn JPY) (S
Slide 9: Announced: In-licensing of vamorolone (AGAMREE) for DMD
Announced: In-licensing of vamorolone (AGAMREE®) for DMD Commercial There is no established therapy for DMD other than corticosteroids in Japan Vamorolone (AGAMREE®) Duchenne Muscular Dystrophy (DMD) • First-in-class drug candidate that binds • DMD is a rare and life-threatening neuromuscular disord
Slide 10: Vamorolone (AGAMREE) addresses the need for a tolerable steroid
Vamorolone (AGAMREE®) addresses the need for a tolerable steroid Commercial Compared with conventional corticosteroid therapy, the risk of treatment-related adverse events is reduced • Vamorolone confronts the limitations of standard Consensus sales forecast of vamorolone in other countries corticos
Slide 11: Synergy with Pivlaz
Synergy with Pivlaz Commercial DMD treatment is concentrated in a limited number of centers and there is approximately 70% commercial overlap with PIVLAZ, creating significant sales synergies Proportion of prescription volume by hospital Pivlaz target University Hospital/Special Core hospital for Lo
Slide 12: Drug Discovery Platform & Pipeline Update
Drug Discovery Platform & Pipeline Update
Slide 13: Portfolio of drugs developed using our innovative NxWave platform
Portfolio of drugs developed using our innovative NxWave platform Platform Discovery – Preclinical Phase 1 Phase 2 Phase 3 Filed Commercial Vamorolone A PIVLAZ® A IN-HOUSE CNS IMM Duchenne Muscular Dystrophy Cerebral vasospasm EP4 ag. NXE’744 Lucerastat A QUVIVIQTM A Best-in-class SMEs for IBD Fabry
Slide 14: Renewed R&D focus where the science is strongest and the opportunity is greatest
Renewed R&D focus where the science is strongest and the opportunity is greatest Platform IN-HOUSE PORTFOLIO - R&D FOCUS AND PROGRAM PRIORITISATION Discovery Phase 2 ready Phase 2 NXE’149 NXE’744 NXE’732 Discovery candidates GPR52 agonist EP4 agonist EP4 antagonist Obesity, metabolic & endocrine Sch
Slide 15: NXE'149: GPR52 agonist for schizophrenia – Phase 2 ready
NXE’149: GPR52 agonist for schizophrenia – Phase 2 ready Platform A novel first-in-class mechanism to treat positive, negative & cognitive domains of schizophrenia Phase 1 highlights: Phase 2 enablement: ✓ Safe and well tolerated • 3 month GLP toxicology in 2 species ✓ Human PK showed low variabilit
Slide 16: NXE'744: EP4 agonist for inflammatory bowel disease (IBD) – Phase 2 ready
NXE’744: EP4 agonist for inflammatory bowel disease (IBD) – Phase 2 ready Platform A first-in-class GI-targeted agent to promote mucosal healing in IBD Disease Rationale Progress • All approved IBD agents are immunomodulatory in nature and do not • All elements of the first-in-human study have now d
Slide 17: NXE'732: EP4 antagonist is our novel immunotherapy for solid tumors
NXE’732: EP4 antagonist is our novel immunotherapy for solid tumors Platform Phase 2a expansion in process in combination with atezolizumab Disease Rationale Phase 1 trial results • When EP4 is activated, it • The emerging data for NXE-732 points to a potential best-in-class profile dampens immune r
Slide 18: Leveraging our GPCR expertise in areas of highest unmet medical need
We can make a huge impact by leveraging our GPCR expertise in the areas of highest unmet Platform medical need: next-generation small molecules for obesity, metabolic and endocrine disorders Unparalleled GPCR SBDD capabilities • Launched broad new pipeline, advancing next-gen BIC therapies for obesi
Slide 19: Neurocrine is advancing the world's most comprehensive portfolio of muscarinic agonists
Neurocrine is advancing the world’s most comprehensive portfolio of Platform muscarinic agonists to treat neuropsychiatric disorders Stage of Program Mechanism Disease State Development Schizophrenia Phase 3 Direclidine M4 Agonist Bipolar Mania Phase 2 Dual M1/M4 Schizophrenia / LAI NBI-’570 Phase 2
Slide 20: Centessa is advancing ORX750, a potential best-in-class Orexin Receptor 2 agonist
Centessa is advancing ORX750, a potential best-in-class Orexin Receptor Platorm 2 agonist for treatment of NT1, NT2 and IH Potential BIC for NT1, NT2 and IH Phase 2a study update Endpoints Maintenance of >20 min change at 1.5mg vs baseline (with half of participants Wakefulness Test >30 min). NT1 (M
Slide 21: The Big Picture
The Big Picture
Slide 22: Our 2030 vision is to build a high growth, highly profitable Japanese biopharma
Our 2030 vision is to build a high growth, highly profitable Japanese biopharma JPY Bn Royalties from WAVE1 + WAVE2 create step-change WAVE2 WAVE2 Royalty Royalty Potential royalty from next generation Only 1-2 launches from seven pipelines. WAVE1 drives significant upside WAVE1 WAVE1 Royalty Royalt
Slide 23: Looking ahead to potential catalysts in 2026
Looking ahead to potential catalysts in 2026* PROGRAM PARTNER TIMING EVENT ORX750 (OX2 agonist) Q1 2026 Phase 2a data across NT1, NT2, and IH ORX750 (OX2 agonist) Q1 2026 Registrational program start in NT1/NT2/IH ORX142 (OX2 agonist) Q1 2026 Phase 2 study start ORX489 (OX2 agonist) Q1 2026 Phase 1
Slide 24: Questions?
~ Questions? Nxera:™
Slide 25: Thank you
Thank you 25 BREAKTHROUGHS IN PROGRESS ● BREAKTHROUGHS IN PROGRESS ● BREAKTHROUGHS IN PROGRESS
Nxera Pharma — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix